AbbVie reports promising early results for novel obesity therapy ABBV-295

ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks

DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial

DiaMedica said it plans to launch the trial later in 2026

Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

The company announced positive topline data from the Phase II ZUPREME-1 trial

Sea Urchin spines inspire breakthrough sensor that detects water flow instantly

Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals

FUJIFILM Biotechnologies launches purification technology for biologics

ShunzymeX leverages a proprietary protease to streamline purification

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder

Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy

SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum

Bioxytran reports 90% day-5 viral clearance in COVID-19 trial at highest dose of ProLectin-M

Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile

Medi Assist teams up with LawtonAsia to bring AI-powered health-tech to Southeast Asia

The collaboration will leverage Medi Assist’s proprietary technology to streamline claims processing, enhance transparency, and deliver smarter health benefits to policyholders in the region

Zydus receives final approvals from USFDA for Ivermectin Tablets USP

Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans